Erratum: Department of Error (The Lancet (2018) 390 (10095)(648) (S0140673617300624) (10.1016/S0140-6736(17)30062-4));Haemolytic uraemic syndrome

The Lancet

Volumn 390, Issue 10095, 2017, Pages 681-696

  Fakhouri, Fadi ^a   Zuber, Julien ^b   Frémeaux Bacchi, Véronique ^c   Loirat, Chantal ^d  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; GENETICS; HEMOLYTIC UREMIC SYNDROME; HUMAN; INCIDENCE; KIDNEY TRANSPLANTATION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PNEUMOCOCCAL INFECTION; PREGNANCY; PRIORITY JOURNAL; REVIEW; CHILD; FEMALE; PREGNANCY COMPLICATION; RECURRENT DISEASE; TREATMENT OUTCOME;

ANTIINFECTIVE AGENT; BIOLOGICAL PRODUCT;

ANTI-BACTERIAL AGENTS; BIOLOGICAL PRODUCTS; CHILD; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY TRANSPLANTATION; PREGNANCY; PREGNANCY COMPLICATIONS; RECURRENCE; TREATMENT OUTCOME;

EID: 85013785320     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31055-3     Document Type: Erratum

References (161)

1. Loirat, C, Fakhouri, F, Ariceta, G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31 (2016), 15–39.
2. Fremeaux-Bacchi, V, Fakhouri, F, Garnier, A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8 (2013), 554–562.
3. Noris, M, Caprioli, J, Bresin, E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5 (2010), 1844–1859.
4. Fischer, S, Huemer, M, Baumgartner, M, et al. Clinical presentation and outcome in a series of 88 patients with the cblC defect. J Inherit Metab Dis 37 (2014), 831–840.
5. Huemer, M, Scholl-Burgi, S, Hadaya, K, et al. Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy. Orphanet J Rare Dis, 9, 2014, 161.
6. Lemaire, M, Fremeaux-Bacchi, V, Schaefer, F, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 45 (2013), 531–536.
7. Pai, R, Moore, MR, Pilishvili, T, Gertz, RE, Whitney, CG, Beall, B, Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 192 (2005), 1988–1995.
8. Veesenmeyer, AF, Edmonson, MB, Trends in US hospital stays for Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Infect Dis J 32 (2013), 731–735.
9. Banerjee, R, Hersh, AL, Newland, J, et al. Streptococcus pneumoniae-associated hemolytic uremic syndrome among children in North America. Pediatr Infect Dis J 30 (2011), 736–739.
10. Ong, KL, Apostal, M, Comstock, N, et al. Strategies for surveillance of pediatric hemolytic uremic syndrome: Foodborne Diseases Active Surveillance Network (FoodNet), 2000–2007. Clin Infect Dis 54:suppl 5 (2012), S424–S431.
11. Bruyand, M, Mariani-Kurkdjian, P, Gouali, M, Van Cauteren, D, de Valk H et le réseau des néphrologues pédiatres. Surveillance du syndrome hémolytique et urémique post-diarrhéique chez l'enfant de moins de 15 ans en France en 2014. Institut de veille sanitaire. http://invs.santepubliquefrance.fr/content/download/114287/401538/version/2/file/Bilan_SHU_2014.pdf, 2014 (accessed Oct 30, 2015).
12. Ardissino, G, Salardi, S, Colombo, E, et al. Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network. Eur J Pediatr 175 (2016), 465–473.
13. Guirro, M, Piazza, RM, de Souza, RL, Guth, BE, Humoral immune response to Shiga Toxin 2 (Stx2) among Brazilian urban children with hemolytic uremic syndrome and healthy controls. BMC Infect Dis, 14, 2014, 320.
14. Rivas, M, Chinen, I, Miliwebsky, E, Masana, M, Risk factors for Shiga toxin-producing Escherichia coli-associated human diseases. Microbiol Spectr, 2, 2014.
15. Frank, C, Werber, D, Cramer, JP, et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 365 (2011), 1771–1780.
16. Buchholz, U, Bernard, H, Werber, D, et al. German outbreak of Escherichia coli O104:H4 associated with sprouts. N Engl J Med 365 (2011), 1763–1770.
17. Gould, LH, Mody, RK, Ong, KL, et al. Increased recognition of non-O157 Shiga toxin-producing Escherichia coli infections in the United States during 2000–2010: epidemiologic features and comparison with E. coli O157 infections. Foodborne Pathog Dis 10 (2013), 453–460.
18. European Centre for Disease Prevention and Control. Annual epidemiological report 2014—food- and waterborne diseases and zoonoses. Shiga toxin/verocytotoxin-producing Escherichia coli infection. http://ecdc.europa.eu/en/publications/Publications/food-waterborne-diseases-annual-epidemiological-report-2014.pdf, 2014 (accessed Oct 30, 2015).
19. Sheerin, NS, Kavanagh, D, Goodship, TH, Johnson, S, A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience. QJM 109 (2016), 27–33.
20. Johnson, S, Stojanovic, J, Ariceta, G, et al. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol 29 (2014), 1967–1978.
21. Petruzziello-Pellegrini, TN, Yuen, DA, Page, AV, et al. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. J Clin Invest 122 (2012), 759–776.
22. Morigi, M, Galbusera, M, Gastoldi, S, et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 187 (2011), 172–180.
23. Spinale, JM, Ruebner, RL, Kaplan, BS, Copelovitch, L, Update on Streptococcus pneumoniae associated hemolytic uremic syndrome. Curr Opin Pediatr 25 (2013), 203–208.
24. Loirat, C, Saland, J, Bitzan, M, Management of hemolytic uremic syndrome. Presse Med 41 (2012), e115–e135.
25. Bruneau, S, Neel, M, Roumenina, LT, et al. Loss of DGKɛ induces endothelial cell activation and death independently of complement activation. Blood 125 (2015), 1038–1046.
26. Martinelli, D, Deodato, F, Dionisi-Vici, C, Cobalamin C defect: natural history, pathophysiology, and treatment. J Inherit Metab Dis 34 (2011), 127–135.
27. Undas, A, Brozek, J, Szczeklik, A, Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost 94 (2005), 907–915.
28. Geraghty, MT, Perlman, EJ, Martin, LS, et al. Cobalamin C defect associated with hemolytic-uremic syndrome. J Pediatr 120 (1992), 934–937.
29. Tsai, JC, Perrella, MA, Yoshizumi, M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 91 (1994), 6369–6373.
30. Fremeaux-Bacchi, V, Miller, EC, Liszewski, MK, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112 (2008), 4948–4952.
31. Goicoechea de Jorge, E, Harris, CL, Esparza-Gordillo, J, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 104 (2007), 240–245.
32. Noris, M, Remuzzi, G, Atypical hemolytic-uremic syndrome. N Engl J Med 361 (2009), 1676–1687.
33. Lechner, K, Obermeier, HL, Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine 91 (2012), 195–205.
34. Morton, JM, George, JN, Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer. J Oncol Pract 12 (2016), 523–530.
35. Favre, GA, Touzot, M, Fremeaux-Bacchi, V, et al. Malignancy and thrombotic microangiopathy or atypical haemolytic and uraemic syndrome?. Br J Haematol 166 (2014), 802–805.
36. Eremina, V, Jefferson, JA, Kowalewska, J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358 (2008), 1129–1136.
37. Al Ustwani, O, Lohr, J, Dy, G, et al. Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. J Gastrointest Oncol 5 (2014), e30–e33.
38. Faguer, S, Huart, A, Fremeaux-Bacchi, V, Ribes, D, Chauveau, D, Eculizumab and drug-induced haemolytic-uraemic syndrome. Clin Kidney J 6 (2013), 484–485.
39. Al-Nouri, ZL, Reese, JA, Terrell, DR, Vesely, SK, George, JN, Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 125 (2015), 616–618.
40. Reese, JA, Bougie, DW, Curtis, BR, et al. Drug-induced thrombotic microangiopathy: experience of the Oklahoma registry and the BloodCenter of Wisconsin. Am J Hematol 90 (2015), 406–410.
41. George, JN, Hematopoietic stem cell transplantation-associated thrombotic microangiopathy: defining a disorder. Bone Marrow Transplant 41 (2008), 917–918.
42. Jodele, S, Laskin, BL, Dandoy, CE, et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 29 (2015), 191–204.
43. Daly, AS, Xenocostas, A, Lipton, JH, Transplantation-associated thrombotic microangiopathy: twenty-two years later. Bone Marrow Transplant 30 (2002), 709–715.
44. Kennedy, GA, Kearey, N, Bleakley, S, Butler, J, Mudie, K, Durrant, S, Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange. Bone Marrow Transplant 45 (2010), 699–704.
45. Jodele, S, Licht, C, Goebel, J, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 122 (2013), 2003–2007.
46. Jodele, S, Zhang, K, Zou, F, et al. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood 127 (2016), 989–996.
47. Laskin, BL, Maisel, J, Goebel, J, et al. Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transplantation 96 (2013), 217–223.
48. de Fontbrune, FS, Galambrun, C, Sirvent, A, et al. Use of Eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation 99 (2015), 1953–1959.
49. Jodele, S, Fukuda, T, Vinks, A, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 20 (2014), 518–525.
50. Le Quintrec, M, Lionet, A, Kamar, N, et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 8 (2008), 1694–1701.
51. Safa, K, Logan, MS, Batal, I, Gabardi, S, Rennke, HG, Abdi, R, Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: a case report. Clin Nephrol 83 (2015), 125–129.
52. Chandran, S, Baxter-Lowe, L, Olson, JL, Tomlanovich, SJ, Webber, A, Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation—a case report. Transplant Proc 43 (2011), 2097–2101.
53. Wilson, CH, Brown, AL, White, SA, Goodship, TH, Sheerin, NS, Manas, DM, Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation 92 (2011), e42–e43.
54. Gervasoni, C, Ridolfo, AL, Vaccarezza, M, et al. Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. Clin Infect Dis 35 (2002), 1534–1540.
55. George, JN, Terrell, DR, Vesely, SK, Kremer Hovinga, JA, Lammle, B, Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. Presse Med 41 (2012), e177–e188.
56. Rerolle, JP, Canaud, G, Fakhouri, F, et al. Thrombotic microangiopathy and hypothermia in an HIV-positive patient: importance of cytomegalovirus infection. Scand J Infect Dis 36 (2004), 234–237.
57. Belford, A, Myles, O, Magill, A, Wang, J, Myhand, RC, Waselenko, JK, Thrombotic microangiopathy (TMA) and stroke due to human herpesvirus-6 (HHV-6) reactivation in an adult receiving high-dose melphalan with autologous peripheral stem cell transplantation. Am J Hematol 76 (2004), 156–162.
58. Chua, JS, Baelde, HJ, Zandbergen, M, et al. Complement factor C4d is a common denominator in thrombotic microangiopathy. J Am Soc Nephrol 26 (2015), 2239–2247.
59. Descombes, E, Droz, D, Drouet, L, Grunfeld, JP, Lesavre, P, Renal vascular lesions in lupus nephritis. Medicine 76 (1997), 355–368.
60. El-Husseini, A, Hannan, S, Awad, A, Jennings, S, Cornea, V, Sawaya, BP, Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis 65 (2015), 127–130.
61. Coppo, R, Peruzzi, L, Amore, A, et al. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 30 (2015), 167–172.
62. Giannakopoulos, B, Krilis, SA, The pathogenesis of the antiphospholipid syndrome. N Engl J Med 368 (2013), 1033–1044.
63. Girardi, G, Berman, J, Redecha, P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 112 (2003), 1644–1654.
64. Redecha, P, Tilley, R, Tencati, M, et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 110 (2007), 2423–2431.
65. Gropp, K, Weber, N, Reuter, M, et al. β(2)-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator. Blood 118 (2011), 2774–2783.
66. Zikos, TA, Sokolove, J, Ahuja, N, Berube, C, Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome. J Clin Rheumatol 21 (2015), 311–313.
67. Kronbichler, A, Frank, R, Kirschfink, M, et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine, 93, 2014, e143.
68. Bakhtar, O, Thajudeen, B, Braunhut, BL, et al. A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab. Transplantation 98 (2014), e17–e18.
69. Couvrat-Desvergnes, G, Masseau, A, Benveniste, O, et al. The spectrum of renal involvement in patients with inflammatory myopathies. Medicine 93 (2014), 33–41.
70. Servais, A, Noel, LH, Roumenina, LT, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82 (2012), 454–464.
71. Manenti, L, Vaglio, A, Gnappi, E, et al. Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis. Clin J Am Soc Nephrol 10 (2015), 2143–2151.
72. Fakhouri, F, Roumenina, L, Provot, F, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 21 (2010), 859–867.
73. Ardissino, G, Wally Ossola, M, Baffero, GM, Rigotti, A, Cugno, M, Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol 122 (2013), 487–489.
74. De Sousa Amorim, E, Blasco, M, Quintana, L, Sole, M, de Cordoba, SR, Campistol, JM, Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management. J Nephrol 28 (2015), 641–645.
75. Zeisler, H, Llurba, E, Chantraine, F, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med 374 (2016), 13–22.
76. Crovetto, F, Borsa, N, Acaia, B, et al. The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. J Matern Fetal Neonatal Med 25 (2012), 2322–2325.
77. Salmon, JE, Heuser, C, Triebwasser, M, et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med, 8, 2011, e1001013.
78. Frimat, M, Decambron, M, Lebas, C, et al. Renal cortical necrosis in postpartum hemorrhage: a case series. Am J Kidney Dis 68 (2016), 50–57.
79. Zhu, J, Chaki, M, Lu, D, et al. Loss of diacylglycerol kinase epsilon in mice causes endothelial distress and impairs glomerular Cox-2 and PGE2 production. Am J Physiol Renal Physiol 310 (2016), F895–F908.
80. Ozaltin, F, Li, B, Rauhauser, A, et al. DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol 24 (2013), 377–384.
81. Locatelli, M, Buelli, S, Pezzotta, A, et al. Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement. J Am Soc Nephrol 25 (2014), 1786–1798.
82. Bresin, E, Rurali, E, Caprioli, J, et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 24 (2013), 475–486.
83. Rodriguez, E, Rallapalli, PM, Osborne, AJ, Perkins, SJ, New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3. Biosci Rep, 34, 2014, e00146.
84. Lek, M, Karczewski, KJ, Minikel, EV, et al., Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536 (2016), 285–291.
85. Richards, S, Aziz, N, Bale, S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17 (2015), 405–424.
86. Delvaeye, M, Noris, M, De Vriese, A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 361 (2009), 345–357.
87. Bu, F, Maga, T, Meyer, NC, et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 25 (2014), 55–64.
88. Rosales, A, Hofer, J, Zimmerhackl, LB, et al. Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis 54 (2012), 1413–1421.
89. Mody, RK, Gu, W, Griffin, PM, et al. Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death. J Pediatr 166 (2015), 1022–1029.
90. Spinale, JM, Ruebner, RL, Copelovitch, L, Kaplan, BS, Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 28 (2013), 2097–2105.
91. Chiurchiu, C, Firrincieli, A, Santostefano, M, Fusaroli, M, Remuzzi, G, Ruggenenti, P, Adult nondiarrhea hemolytic uremic syndrome associated with Shiga toxin Escherichia coli O157:H7 bacteremia and urinary tract infection. Am J Kidney Dis, 41, 2003, e4.
92. Coppo, P, Schwarzinger, M, Buffet, M, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One, 5, 2010, e10208.
93. Fakhouri, F, Delmas, Y, Provot, F, et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am J Kidney Dis 63 (2014), 40–48.
94. Mathew, RO, Nayer, A, Asif, A, The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy. J Am Soc Hypertens 10 (2015), 352–359.
95. Nathanson, S, Kwon, T, Elmaleh, M, et al. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 5 (2010), 1218–1228.
96. Magnus, T, Rother, J, Simova, O, et al. The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak. Brain 135 (2012), 1850–1859.
97. Durkan, AM, Kim, S, Craig, J, Elliott, E, The long-term outcomes of atypical haemolytic uraemic syndrome: a national surveillance study. Arch Dis Child 101 (2016), 387–391.
98. Malina, M, Gulati, A, Bagga, A, Majid, MA, Simkova, E, Schaefer, F, Peripheral gangrene in children with atypical hemolytic uremic syndrome. Pediatrics 131 (2013), e331–e335.
99. Rigothier, C, Delmas, Y, Roumenina, LT, et al. Distal angiopathy and atypical hemolytic uremic syndrome: clinical and functional properties of an anti-factor H IgAλ antibody. Am J Kidney Dis 66 (2015), 331–336.
100. Ardissino, G, Tel, F, Testa, S, et al. Skin involvement in atypical hemolytic uremic syndrome. Am J Kidney Dis 63 (2014), 652–655.
101. Dragon-Durey, MA, Sethi, SK, Bagga, A, et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 21 (2010), 2180–2187.
102. Noris, M, Remuzzi, G, Cardiovascular complications in atypical haemolytic uraemic syndrome. Nat Rev Nephrol 10 (2014), 174–180.
103. Hu, H, Nagra, A, Haq, MR, Gilbert, RD, Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement. Pediatr Nephrol 29 (2014), 1103–1106.
104. Emirova, K, Volokhina, E, Tolstova, E, van den Heuvel, B, Recovery of renal function after long-term dialysis and resolution of cardiomyopathy in a patient with aHUS receiving eculizumab. BMJ Case Rep, 2016, 10.1136/bcr-2015-213928 published online Feb 15.
105. Kokame, K, Nobe, Y, Kokubo, Y, Okayama, A, Miyata, T, FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129 (2005), 93–100.
106. Mody, RK, Luna-Gierke, RE, Jones, TF, et al. Infections in pediatric postdiarrheal hemolytic uremic syndrome: factors associated with identifying shiga toxin-producing Escherichia coli. Arch Pediatr Adolesc Med 166 (2012), 902–909.
107. Dallman, TJ, Byrne, L, Launders, N, Glen, K, Grant, KA, Jenkins, C, The utility and public health implications of PCR and whole genome sequencing for the detection and investigation of an outbreak of Shiga toxin-producing Escherichia coli serogroup O26:H11. Epidemiol Infect 143 (2015), 1672–1680.
108. Scully, M, Goodship, T, How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol 164 (2014), 759–766.
109. Zuber, J, Fakhouri, F, Roumenina, LT, Loirat, C, Fremeaux-Bacchi, V, Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8 (2012), 643–657.
110. Koenig, JC, Rutsch, F, Bockmeyer, C, et al. Nephrotic syndrome and thrombotic microangiopathy caused by cobalamin C deficiency. Pediatr Nephrol 30 (2015), 1203–1206.
111. Cornec-Le Gall, E, Delmas, Y, De Parscau, L, et al. Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. Am J Kidney Dis 63 (2014), 119–123.
112. Grange, S, Bekri, S, Artaud-Macari, E, et al. Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency. Lancet 386 (2015), 1011–1012.
113. George, JN, Cobalamin C deficiency-associated thrombotic microangiopathy: uncommon or unrecognised?. Lancet, 386, 2015, 1012.
114. Cataland, SR, Holers, VM, Geyer, S, Yang, S, Wu, HM, Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood 123 (2014), 3733–3738.
115. Noris, M, Galbusera, M, Gastoldi, S, et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124 (2014), 1715–1726.
116. Bu, F, Meyer, NC, Zhang, Y, et al. Soluble c5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome. Am J Kidney Dis 65 (2015), 968–969.
117. Gavriilaki, E, Yuan, X, Ye, Z, et al. Modified Ham test for atypical hemolytic uremic syndrome. Blood 125 (2015), 3637–3646.
118. Gould, LH, Demma, L, Jones, TF, et al. Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, 2000–2006. Clin Infect Dis 49 (2009), 1480–1485.
119. Ardissino, G, Dacco, V, Testa, S, et al. Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome. Pediatr Nephrol 30 (2015), 345–352.
120. Ardissino, G, Tel, F, Possenti, I, et al. Early volume expansion and outcomes of hemolytic uremic syndrome. Pediatrics 137 (2016), 1–9.
121. Safdar, N, Said, A, Gangnon, RE, Maki, DG, Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 288 (2002), 996–1001.
122. Freedman, SB, Xie, J, Neufeld, MS, Hamilton, WL, Hartling, L, Tarr, PI, Shiga toxin-producing Escherichia coli infection, antibiotics, and risk of developing hemolytic uremic syndrome: a meta-analysis. Clin Infect Dis 62 (2016), 1251–1258.
123. Menne, J, Nitschke, M, Stingele, R, et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ, 345, 2012, e4565.
124. Wong, CS, Mooney, JC, Brandt, JR, et al. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis 55 (2012), 33–41.
125. Smith, KE, Wilker, PR, Reiter, PL, Hedican, EB, Bender, JB, Hedberg, CW, Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota. Pediatr Infect Dis J 31 (2012), 37–41.
126. Nitschke, M, Sayk, F, Hartel, C, et al. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA 307 (2012), 1046–1052.
127. Vonberg, RP, Hohle, M, Aepfelbacher, M, et al. Duration of fecal shedding of Shiga toxin-producing Escherichia coli O104:H4 in patients infected during the 2011 outbreak in Germany: a multicenter study. Clin Infect Dis 56 (2013), 1132–1140.
128. Agger, M, Scheutz, F, Villumsen, S, Molbak, K, Petersen, AM, Antibiotic treatment of verocytotoxin-producing Escherichia coli (VTEC) infection: a systematic review and a proposal. J Antimicrob Chemother 70 (2015), 2440–2446.
129. Loos, S, Ahlenstiel, T, Kranz, B, et al. An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 55 (2012), 753–759.
130. Kielstein, JT, Beutel, G, Fleig, S, et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC–HUS registry. Nephrol Dial Transplant 27 (2012), 3807–3815.
131. Greinacher, A, Friesecke, S, Abel, P, et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 378 (2011), 1166–1173.
132. Combe, C, Bui, HN, de Precigout, V, Hilbert, G, Delmas, Y, Immunoadsorption in patients with haemolytic uraemic syndrome. Lancet 379 (2012), 517–518.
133. Immunoadsorption in patients with haemolytic uraemic syndrome—Authors' reply. Lancet 379 (2012), 518–519.
134. Melton-Celsa, AR, O'Brien, AD, New therapeutic developments against Shiga toxin-producing Escherichia coli. Microbiol Spectr, 2, 2014.
135. Lapeyraque, AL, Malina, M, Fremeaux-Bacchi, V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364 (2011), 2561–2563.
136. Delmas, Y, Vendrely, B, Clouzeau, B, et al. Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant 29 (2014), 565–572.
137. Saini, A, Emke, AR, Silva, MC, Perlman, SJ, Response to eculizumab in Escherichia coli O157: H7-induced hemolytic uremic syndrome with severe neurological manifestations. Clin Pediatr 54 (2015), 387–389.
138. Pape, L, Hartmann, H, Bange, FC, Suerbaum, S, Bueltmann, E, Ahlenstiel-Grunow, T, Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement. Medicine, 94, 2015, e1000.
139. Greenbaum, LA, Fila, M, Ardissino, G, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89 (2016), 701–711.
140. Rees, L, Greenbaum, LA, Fila, M, et al. A prospective study of paediatric patients with atypical hemolytic uremic syndrome treated with eculizumab: 1-year update (abstract). Pediatr Nephrol, 30, 2015, 1564.
141. Legendre, CM, Licht, C, Muus, P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368 (2013), 2169–2181.
142. Licht, C, Greenbaum, LA, Muus, P, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87 (2015), 1061–1073.
143. Fakhouri, F, Hourmant, M, Campistol, JM, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 68 (2016), 84–93.
144. Fakhouri, F, Hourmant, M, Campistol, JM, et al. Eculizumab inhibits thrombotic microangiopathy, and improves renal function in adult atypical hemolytic uremic syndrome patients: 1-year update. J Am Soc Nephrol, 25, 2014, 751A.
145. Cofiell, R, Kukreja, A, Bedard, K, et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 125 (2015), 3253–3262.
146. Gomez-Cibeira, E, Ivanovic-Barbeito, Y, Gutierrez-Martinez, E, et al. Eculizumab-related progressive multifocal leukoencephalopathy. Neurology 86 (2016), 399–400.
147. Walle, JV, Delmas, Y, Ardissino, G, Wang, J, Kincaid, JF, Haller, H, Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol, 2016, 10.1007/s40620-016-0288-3 published online March 19.
148. Ito, N, Hataya, H, Saida, K, et al. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol 20 (2015), 265–272.
149. Avila, A, Vizcaino, B, Molina, P, Gavela, E, Perez-Ebri, M, Pallardo, L, Remission of aHUS neurological damage with eculizumab. Clin Kidney J 8 (2015), 232–236.
150. Baskin, E, Gulleroglu, K, Kantar, A, Bayrakci, U, Ozkaya, O, Success of eculizumab in the treatment of atypical hemolytic uremic syndrome. Pediatr Nephrol 30 (2015), 783–789.
151. Greenwood, GT, Case report of atypical hemolytic uremic syndrome with retinal arterial and venous occlusion treated with eculizumab. Int Med Case Rep J 8 (2015), 235–239.
152. Cugno, M, Gualtierotti, R, Possenti, I, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 12 (2014), 1440–1508.
153. Walport, MJ, Complement. First of two parts. N Engl J Med 344 (2001), 1058–1066.
154. Hisano, M, Ashida, A, Nakano, E, et al. Autoimmune-type atypical hemolytic uremic syndrome treated with eculizumab as first-line therapy. Pediatr Int 57 (2015), 313–317.
155. Noone, D, Waters, A, Pluthero, FG, et al. Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol 29 (2014), 841–851.
156. Green, H, Harari, E, Davidovits, M, et al. Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab. Ren Fail 36 (2014), 1119–1121.
157. Diamante Chiodini, B, Davin, JC, Corazza, F, et al. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome. Pediatrics 133 (2014), e1764–e1768.
158. Zschiedrich, S, Prager, EP, Kuehn, EW, Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab. Ann Intern Med, 159, 2013, 76.
159. Ardissino, G, Wally Ossola, M, Baffero, GM, Rigotti, A, Cugno, M, Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol 122 (2012), 487–489.
160. Kelly, RJ, Hochsmann, B, Szer, J, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 373 (2015), 1032–1039.
161. Le Quintrec, M, Zuber, J, Moulin, B, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 13 (2013), 663–675.